Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

Healthcare Biotechnology Cannabis


NDAQ:INM - Post by User

InMed Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(9)
•••
Comment by mahoonon Jan 23, 2020 3:19pm
137 Views
Post# 30590491

RE:RE:RE:Gap Up As Expected

RE:RE:RE:Gap Up As Expected More than likely I agree. 
But if their Biosynthesis Program is feasible InMed should not have any problem having their 06/20 warrants @ $1.25 being exercised. I think that the company is relying on this as it will feed another $20m + into their coffers .  We should be getting an update on this within the next few weeks as per CEO Eric Adams in his latest letter to shareholders.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities